New photobiomodulation device for prevention and cure of radiotherapy-induced oral mucositis and dermatitis: results of the prospective Safe PBM study.

Support Care Cancer

Département de Radiothérapie, Institut de Cancérologie Lucien Neuwirth, 108 bis, avenue Albert Raimond, 42270, Saint-Priest en Jarez, France.

Published: February 2022

Purpose: The study aims to assess the feasibility, safety, and tolerability of CareMin650, a new photobiomodulation device, in patients treated by radiotherapy (RT) and to collect preliminary data on efficacy for prevention and treatment of oral mucositis (OM) and radiation dermatitis (RD).

Methods: Safe PBM is a French, multicentric, prospective, non-comparative study which include patients with head and neck cancer (H&NC, cohort A) or breast cancer (BC, cohort B) treated in prophylactic (cohorts A1 and B1) or curative setting (cohort A2 and B2). Prophylactic treatment was administered from D1 to end of RT, at a dose of 3 J/cm. Curative treatment started when a grade 1 to grade 3 lesion had occurred and was pursued until end of RT. Primary endpoint was incidence of device-related adverse events (AEs). OM and RD lesions were graded according to CTCAE V3.

Results: Overall, 72 patients were included (22, 9, 23, and 18 in cohorts A1, A2, B1, and B2, respectively). No device-related AE was reported after 1312 CareMin650 sessions. In cohorts A1 and B1, median time to first OM or RD lesion was 20 days. One BC patient developed G3 RD after completion of RT and discontinuation of CareMin650. Four H&NC patients developed G3 OM. In cohorts A2 and B2, lesions improved or stabilized in 71% of patients. Rates of satisfaction were high among patients and users.

Conclusion: CareMin650 is feasible, safe, and well tolerated for preventive or curative treatment of OM and RD in cancer patients treated with RT. Preliminary efficacy results are promising.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449745PMC
http://dx.doi.org/10.1007/s00520-021-06574-2DOI Listing

Publication Analysis

Top Keywords

photobiomodulation device
8
oral mucositis
8
safe pbm
8
patients treated
8
curative treatment
8
patients
7
device prevention
4
prevention cure
4
cure radiotherapy-induced
4
radiotherapy-induced oral
4

Similar Publications

Fractional 1064 nm Nd: YAG picosecond lasers for the treatment of traumatic scars: a retrospective study.

Lasers Med Sci

December 2024

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangwangmiao Street 12, Xuanwu District, Nanjing, Jiangsu Province, 210042, China.

Traumatic scars negatively impact the patient's quality of life. Fractional 1064 nm Nd: YAG picosecond laser improves scars. However, the effect varies among individuals.

View Article and Find Full Text PDF

Transversal maxillary deficiency is a prevalent skeletal issue that can be addressed using various devices and methods, including rapid maxillary expansion (RME) and surgically assisted rapid maxillary expansion (SARME). These techniques involve the separation and regeneration of the midpalatal suture (MPS). Laser therapies, such as low-level laser therapy (LLLT) and photobiomodulation (PBM), have been proposed to improve biological wound or bone healing.

View Article and Find Full Text PDF

Background: Alveolar osteitis is a type of small-scale osteomyelitis of the alveolar bone that occurs after tooth extraction, the etiology of which remains unknown, and alternative methods are being investigated for its treatment. The aim of this study was to compare the effectiveness of advanced platelet-rich fibrin (A-PRF), photobiomodulation (PBM), and Alveogyl (butamben, idoform, eugenol), which have shown success in the treatment of alveolar osteitis, with that of pentoxifylline (PTX) to determine whether PTX could be an alternative treatment for alveolar osteitis.

Methods: This study included 80 healthy volunteers diagnosed with alveolar osteitis in the extraction sockets of their mandibular first, second, and third molars.

View Article and Find Full Text PDF

Near-infrared light therapy normalizes amyloid load, neuronal lipid membrane order, rafts and cholesterol level in Alzheimer's disease.

J Photochem Photobiol B

December 2024

Center for Biomedical Photonics, College of Physics and Optoelectronic Engineering, Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, Shenzhen University, Shenzhen 518060, PR China. Electronic address:

Cholesterol dysregulation, disorder of neuronal membrane lipid packing, and lipid rafts lead to the synthesis and accumulation of toxic amyloid-β (Aβ), contributing to the development of Alzheimer's disease (AD). Our study shows that near-infrared (NIR) transcranial photobiomodulation therapy (tPBMT) can reduce Aβ load and restore the properties of neuronal plasma membrane, including Aβ production, bilayer order, rafts, lipid content, and Ca channels during AD. Mice in the experiments were exposed to 808-nm LED for 1 h daily over 3 months.

View Article and Find Full Text PDF

Introduction: This study aims to determine if intraoral 850 nm LED irradiation could reduce the duration of lower anterior crowding alignment.

Methods: In a parallel-designed, randomized controlled clinical trial 60 patients with 2 to 6 mm of lower incisor crowding who need non-extraction treatment, were randomly assigned to the intervention and control groups by block randomization (36 females, 24 males, mean age: 19.93 ± 3.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!